Perrigo Co. Plc (PRGO)

Perrigo's stock price has experienced a significant decline over the past year, with a 53.47% change. On November 5, 2025, Perrigo's stock price fell by $5.09, or 25.2%, to close at $15.10 per share following the announcement of disappointing financial results for the third quarter ended September 27, 2025, a revised fiscal year 2025 outlook, and the initiation of a strategic review of its infant formula business. The company also stated it was reassessing a previously announced $240 million investment in this business. Earlier in August 2025, Perrigo's stock also fell after its Q3 earnings beat but sales missed, and the company cut its 2025 outlook.

While Perrigo's business is not generally seasonal, certain product categories, such as cough/cold/flu and allergy products, do experience seasonality. The capacity of some of Perrigo's manufacturing facilities may be fully utilized at certain times due to consumer and customer demand, the seasonality of these product categories, and new product launches. The company has experienced headwinds from weaker cold-and-flu seasons in the past.

Perrigo Company plc is a global consumer self-care company specializing in over-the-counter (OTC) health and wellness solutions, operating within the Healthcare sector. Since 2018, Perrigo has focused solely on consumer self-care by divesting its animal health and generic pharmaceuticals businesses. In North America, Perrigo is a major provider of private-label consumer health goods, supplying large retailers and is the largest U.S. store brand provider of over-the-counter and infant formula. In Europe, Australia, and parts of Asia, Perrigo generates revenue primarily through its national brands, with key products including Opill®, Compeed®, and Solpadeine®. The company's mission is to improve lives through trusted health and wellness solutions accessible to all.

Perrigo Company plc has a significant global presence, with operations across six continents, including North America, Europe, and Asia. Legally headquartered in Dublin, Ireland, its operational headquarters are in Grand Rapids, Michigan, U.S. The company has manufacturing facilities in the U.S., U.K., Belgium, France, Germany, Austria, China, and Australia, and logistics facilities in the U.S., Mexico, Australia, and various locations throughout Europe. Perrigo's products are sold primarily in North America, Europe, and Australia, as well as other key markets like Israel and China.

Perrigo is recognized as one of the largest consumer health companies globally and a leading provider of consumer self-care products, emphasizing "Quality, Affordable Self-Care Products™". In the past year, Perrigo has focused on a "Stabilize, Streamline, and Strengthen" strategy to enhance its business operations, including streamlining its portfolio and prioritizing assets. The company has also seen its store brand OTC products gain volume share in the U.S. and its key European brands achieve dollar share gains, supported by advertising and innovation.

Perrigo Co. Plc (PRGO) is primarily owned by institutional shareholders, holding approximately 65.21% to 106.24% of the company's stock. Major institutional owners include Price T Rowe Associates Inc /Md/, Vanguard Group Inc, and BlackRock, Inc. Individual investors and public companies hold a smaller portion, with retail investors owning approximately 0.00% to 5.59% and insiders holding around 0.33% to 59.13% of the stock. Michael J. Jandernoa is noted as the largest individual shareholder, owning 41.51 million shares, representing 30.17% of the company.